Protocol summary
-
Study aim
-
Objectives: investigating the effects of a multisite transcranial random noise stimulation (tRNS) on tinnitus loudness, distress, MMN response and electroencephalography in chronic tinnitus subjects.
-
Design
-
Design: it is an interventional, one phase, and randomized, single blinded study. We have two groups: the intervention group in which we will apply the (high frequency) hf-tRNS over the right DLPFC (Dorso Lateral Prefrontal Cortex) followed by (low frequency) lf-tRNS over the auditory cortex in one session. And the control group in which we will apply the lf-tRNS over the auditory cortex only. Each patient in these two groups will take a placebo (Sham stimulation) session before the active tRNS session. There is randomization in allocating patients in groups, but they will take the two treatment stages (placebo & active) without randomization. Patients will be randomly organized into the two groups, but they will take the two treatment stages (placebo & active) without randomization i.e in all cases we will begin with the Sham stimulation. The way of randomization is by drawing a number between 1-32 where numbers from 1 to 16 is referring to the intervention group while numbers from 17 to 32 is referring to the control group. The randomization will be done by using Matlab.
-
Settings and conduct
-
Setting: After signing the consent form, Patients will be allocated randomly into two groups. In each group, each patient blindly will undertake both Sham and tRNS simulations beginning with the Sham one. Each patient will complete the VAS-L and VAS-A (Visual Analogue Scale) before and immediately after each session. In addition, EEG and MMN recording will be taken before and immediately after each session.
-
Participants/Inclusion and exclusion criteria
-
Participants: all patients with chronic nonpulsatile tinnitus (>6 months) can participate in this study with the following entry criteria: age between 20 and 50 years, the behavioral pure-tone audiometry threshold levels of ≤20 dBHL in octave frequencies of 250–2000 Hz and not more than 40 dBHL in frequencies of 4000 -8000 Hz, and the tinnitus intensity moderate to severe; not having a remarkable cognitive problems, a previous formal musical training, or a history of otological, neurological, mental diseases, head trauma, psychiatric disorders, seizure and finally not having a pacemaker or defibrillator.
-
Intervention groups
-
Our intervention is applying transcranial random noise electrical stimulation with two protocols: multisite (auditory and prefrontal), and the auditory cortex. The placebo intervention is given by using the Sham stimulation mode; the current is switched off automatically after a ramp-in of 10 seconds and the session will be given in the same mentioned protocols in active interventions concerning electrode arrays and the time of the session which lasts for 20 minutes.
-
Main outcome variables
-
Tinnitus related loudness, tinnitus related annoyance (distress), MMN amplitude & MMN area under curve, Mean frequency of EEG waves, EEG absolute & relative powers and the EEG activity in ROIs (region of interest) as main outcome measures.
The tinnitus pitch as a secondary variable.
General information
-
Reason for update
-
-
Acronym
-
-
-
IRCT registration information
-
IRCT registration number:
IRCT2017050724360N2
Registration date:
2017-06-30, 1396/04/09
Registration timing:
prospective
Last update:
2017-12-14, 1396/09/23
Update count:
1
-
Registration date
-
2017-06-30, 1396/04/09
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Iran University of Medical Sciences
-
Expected recruitment start date
-
2017-06-01, 1396/03/11
-
Expected recruitment end date
-
2017-10-31, 1396/08/09
-
Actual recruitment start date
-
2017-07-15, 1396/04/24
-
Actual recruitment end date
-
2017-10-28, 1396/08/06
-
Trial completion date
-
empty
-
Scientific title
-
The effect of a multisite transcranial random noise stimulation (tRNS) on tinnitus loudness, distress, mismatch negativity response (MMN) and electroencephalography (QEEG) in subjects with chronic tinnitus
-
Public title
-
The effect of electrical stimulation on treatment of chronic tinnitus
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Right-handedness
Chronic nonpulsatile tinnitus (>6 months)
Age between 20 and 50 years
Normal external and middle ear function and appearance using otoscopy and tympanometry
Behavioral pure-tone audiometry threshold levels of ≤20 dBHL in octave frequencies of 250–2000 Hz and not more than 40 dBHL in frequencies of 4000 -8000 Hz
Moderate to severe tinnitus intensity (THI score over 38-76)
Exclusion criteria:
Remarkable cognitive problems (MMSE over 20);
Previous formal musical training
Depression and anxiety (HADS scores less than 11 from 21 for either depression and anxiety)
A history of otological, neurological, mental diseases, head trauma, pregnancy, psychiatric disorders, dementia, seizure or any organic diseases that cause tinnitus;
Having a pacemaker or defibrillator
Taking specific medication that could modify the stimulation effect: (i.e., amine metabolism drugs: citalopram, sulpiride, and pergolide; amino acid metabolism drugs: lorazepam, rivastigmine. Moreover, voltage-sensitive channel blockers: carbamazepine and flunarizine).
-
Age
-
From 20 years old to 60 years old
-
Gender
-
Both
-
Phase
-
1
-
Groups that have been masked
-
-
Sample size
-
Target sample size:
32
Actual sample size reached:
33
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Patients will be simply randomized into two groups, but they will take the two treatment stages (placebo & active) without randomization i.e in all cases we will begin with the Sham stimulation. The way of randomization is by drawing a number between 1-32 where numbers from 1 to 16 is referring to the intervention group while numbers from 17 to 32 is referring to the control group. The randomization will be done by computer using Matlab.
-
Blinding (investigator's opinion)
-
Single blinded
-
Blinding description
-
All participants have no information about kind of their treatment session (placebo or real). They also have no information about in which group they are participating. However, the researcher knows these details and he is the performer of the experiment.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2017-04-22, 1396/02/02
-
Ethics committee reference number
-
IR.IUMS.REC 1395.9321667001
Health conditions studied
1
-
Description of health condition studied
-
tinnitus
-
ICD-10 code
-
H93.1
-
ICD-10 code description
-
Tinnitus
Primary outcomes
1
-
Description
-
Tinnitus related loudness
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
Visual Analogue Scale (VAS-L)
2
-
Description
-
Tinnitus related annoyance(distress)
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
Visual Analogue Scale (VAS-A)
3
-
Description
-
MMN amplitude
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
MMN software
4
-
Description
-
MMN area under curve
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
MMN software
5
-
Description
-
Mean frequency of EEG waves
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
Mean frequency of EEG waves
6
-
Description
-
EEG absolute powers
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
EEG software
7
-
Description
-
EEG relative powers
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
EEG software
8
-
Description
-
EEG activity in ROIs (region of interest)
-
Timepoint
-
Immediately after the treatment session
-
Method of measurement
-
EEG software (sLORETA)
Secondary outcomes
1
-
Description
-
Tinnitus pitch
-
Timepoint
-
Before treatment
-
Method of measurement
-
Pitch matching
Intervention groups
1
-
Description
-
Control group: in this group the intervention is low frequency-tRNS with the same parameters used in the intervention group with one difference concerning the electrode array. In this concern the whole 20 minutes session will be applied over the auditory cortex (T3, T4). Before the active session the patient will take a sham stimulation session.
-
Category
-
Treatment - Devices
2
-
Description
-
Intervention group: Stimulation is delivered by a battery-driven electrical stimulator (NeuroStim2; Medinateb, Iran) through conductive rubber electrodes, placed in two saline-soaked sponges. In the stimulation mode “noise” there is a random level of current generated for every sample (sampling rate 1280 samples/s). The random numbers are normally distributed; the probability density function follows a bell-shaped curve. In the frequency spectrum all coefficients have a similar size (“white noise”). The noise signal contains all frequencies up to half of the sampling rate, i.e., a maximum of 640 Hz. In our experiment this frequency spectrum is separated into a low (0.1–100 Hz)-frequency which will be applied over the auditory cortex (AC-tRNS) for 10 minutes followed by the high (101–640 Hz)-frequency spectrum stimulation of the DLPFC (DLPFC-tRNS) for the following 10 minutes to have an active stimulation session of 20 minutes called the multisite one. Because of the statistical characteristics, the signal has no DC offset, provided that the offset is set to zero and the intensity of alternating current is 2.0 mA which, is initially increased in a ramp-like fashion over several seconds (30 s) until reaching 2.0 mA. In the AC-tRNS, the electrodes is placed over the left and right auditory cortices (T3, T4), while in the DLPFC-tRNS they will be placed over the right DLPFC (F4) and the left frontopolar cortex (FP1) as determined by the International 10/20 Electroencephalogram System. In the stimulation mode “sham” the current is switched off automatically after a ramp-in of 30 seconds. Each patient in the group will take a sham stimulation session before taking his/her active intervention without knowing which of them is placebo. The session will be given in the same mentioned protocols in active intervention concerning electrode arrays and the time of the session.
-
Category
-
Treatment - Devices
1
-
Sponsor
-
-
Grant name
-
-
-
Grant code / Reference number
-
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Iran University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available